Overview
Rockwell Medical Q3 net sales fell 44% yr/yr, missing analyst expectations
Company achieved profitability on an adjusted EBITDA basis for Q3 2025
Rockwell Medical's cash position increased to $23.7 mln at September 30, 2025
Outlook
Rockwell Medical reiterates 2025 net sales guidance of $65 mln to $70 mln
Company expects 2025 gross margin between 16% and 18%
Rockwell Medical projects 2025 adjusted EBITDA between ($0.5) mln and $0.5 mln
Result Drivers
CUSTOMER LOSS - Net sales decreased due to largest customer transitioning to another supplier
NEW AGREEMENTS - Co signed new long-term product purchasing agreements with medical centers and hospital systems
OPERATIONAL EFFICIENCY - Co focused on right-sizing organization to enhance operational efficiency and support growth
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Sales | Miss | $15.93 mln | $16.20 mln (2 Analysts) |
Q3 EPS | -$0.05 | ||
Q3 Net Income | -$1.75 mln | ||
Q3 Gross Profit | $2.27 mln | ||
Q3 Operating Income | -$1.58 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Rockwell Medical Inc is $4.00, about 73.8% above its November 11 closing price of $1.05
Press Release: ID:nBw2ygMNSa
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Comments